• search
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Dosage Formulation Services

Dosage Formulation Services

Capability to develop a wide range of dosage forms and added capability to commercialize oral solids and soft gelatin capsules.

Starting with comprehensive pre-formulation services to commercial manufacturing, we provide a full suite of services for oral solid dosage forms and soft gelatin formulations. We offer “Fit for purpose formulation” development for pre-clinical and FIH studies based on molecule pharmacokinetic behavior, excipient compatibility studies and screening of excipients. Our formulation manufacturing facilities are in Hyderabad and Visakhapatnam and are audited by all major regulatory agencies.

Cross-functional teams such as PK-PD, API synthesis, salt screening, toxicology, process engineering, and analytical development teams are co-located and work in an integrated manner for efficient development. Continuous feedback among the teams at each stage of the life cycle helps resolve the issues during the early stage of NCE development and parallel activities help expedite the timelines for product delivery.

Speak to our experts

Oral Solid Dosage Form

We offer integrated oral solid dose services right from pre-formulation services to commercial manufacturing. We provide recommendations for best dosage form to clinic based on the preformulation study results and help customer to choose the fit for purpose dosage form that suites the therapeutic objective.

Pre-formulation services:

Our oral solid pre-formulation services include:

  • API physiochemical characterization
  • Molecule stability behavior
  • Solubility enhancement by various techniques

We provide effective solutions for pre-clinical stage formulation development to enable GLP toxicity studies in a smooth manner in target animal species. Based on DMPK profile of the molecule we also provide recommendations for maximizing the bioavailability of the molecule through solubility and permeability enhancement, gastro retentive formulation and targeted drug delivery systems

We offer pre-clinical supplies of formulations for animal studies from R and D. Our state-of-the-art lab facilities are equipped with miniature lab equipment that enables fit for purpose formulation development using minimum batch size as low as approximately 50 g blend. Key unit operations such as granulation, drying, blending up to coating are capable of handling minimum batch size to enable formulation development using minimal drug substance quantities. We also offer support to veterinary formulations for development of customized formulation.

Solubility enhancement by lipid technology

Lipid formulations are often explored to deliver the molecules through lymphatic pathway. Our portfolio of lipid formulations includes various dosage forms as shown below

“Fit for purpose” dosage form development services for early phase clinical trials (Phase 1 and 2): Insights from the pre-formulation and preclinical studies would be taken into consideration while designing fit for purpose dosage form for First in human and Phase 1 clinical supply. Availability of drug substance quantities are quite a concern in early phase studies for most of the NCEs. Hence, basic formulations such as API filled into capsule/ bottle or powder for extemporaneous suspension/solution are highly preferred during early phase.

In addition to conventional approach, we also have capabilities to enhance the taste of the bitter tasting drug and help to select the type and level of sweetener and flavours using e-tongue technology. Taste masking approaches include use of sweeter and flavour combinations, complexation of molecule using ion exchange resins or cyclodextrins and use of polymer coating to provide taste masking.

We have state of art technology (Xcelodose) for filling of API in capsule with accuracy and precision and support to bring your NCE molecule right from preclinical stage to clinical stage in a cost effective manner.

Most of the times the dosage strengths are not finalized during early phase and time lines for clinical study initiation are critical. At the same time the molecules need modified release to enable desired therapeutic action. In such cases we offer multi particulate technology using pellets or micro/mini tablets that enable dose adjustment based on strength(s) finalization. This approach helps to expedite the development without waiting for dosage strength finalization and at the same time provides enough time and flexibility for the innovator companies for finalization dosage strengths from wide range based on clinical study outcome. Moreover analytical methods are developed to cover wide dose range to avoid re-work once dose strength is finalized.

Multi particulate technology has also been adopted to achieve tailored drug release of actives in fixed dose combination formulation to enable immediate release of one active and delayed/modified release of another active. Overall we offer flexibility in terms of dosage form design and dose selection using state of art technology and high level expertise in the field of dosage form design.

Above approaches help to reduce the cost and time during the early phase clinical trials significantly and help customers to choose dosage strengths in a flexible manner. As scalable formulations are developed, the API requirements are much less as compared to conventional development approach.

Late phase formulation development for phase 3 or commercial supply:

We offer wide variety of dosage forms for late phase development up to commercial manufacturing. Our state of art laboratory equipment help to develop robust formula and process to enable smooth technology transfer. Late phase formulation and dosage form shall be design to enable seamless technology transfer to manufacturing site without any processing issues. We adopt QbD approach and evaluate impact of formulation variables and critical material/process variables on drug product quality attributes during the lab scale development and provide recommendations for successful scale up.

We offer development and manufacturing services of conventional dosage forms such as immediate-release tablets, chewable tablets, orally disintegrating tablets, granules for suspension and capsules.

In addition to hard capsules we also provide service for manufacture of soft gelatin capsules. Soft gelatin capsules are preferred when there are bioavailbility issues, content uniformity issues in case of very low dose formulations. Liquid solution/suspension or semi-solids can be incorporated in to soft gelatin capsules.

In addition to traditional forms, we have the capability of developing and manufacturing highly complex formulations involving bi-layer tablets, multi-particulate systems (Pellets or Mini-tablets in capsules), fixed dose combinations, taste-masked formulations, very low and high-dose products and delayed and modified-release formulations. We provide patient centric solutions for the dosage form design.

We have access to state of art manufacturing facilities that are approved by US FDA, MHRA and WHO to enable seamless cGMP manufacturing of clinical/registration and commercial batches. Most of the manufacturing facilities follow paperless electronic BMR systems and comply to stringent regulatory requirements.

Various unit operations that can be handled in R and D and manufacturing facility are detailed below

Unit operations R and D Scale of operation: 50g – 5 Kg cGMP Execution Scale 10 Kg – 500 Kg
Wet granulation    
Dry granulation/Roll compaction    
Fluid bed granulation    
Wurster coating for delayed release/ modified release    

Parenteral Dosage Forms

Our depth and breadth of experience and specialization in parenteral dosage form development is remarkable which can provide insight, oversight and innovation to be the most successful. We offer the expertise in overcoming the challenges associated with parenteral drug product development such as but not limited to.

  • Solubility enhancement studies
  • Achieving a good compatibility of the drug substances with the excipients
  • Establishing the compatibility of the preparations with the container closure system
  • Stability challenges

A constant focus on key control measures through pre-formulation development to drug product development is provided to meet time-to-market schedules within the prescribed budget. With a portfolio of options to choose from, we partner with customers to find the approach that best achieves their technical goals.

Our dosage forms includes:

  • Aqueous liquid injectables
  • Non-aqueous liquid injectables
  • Lyophilized injectables
  • Ophthalmic and Otic solutions
  • Nasal solutions (drops to be instilled into nostrils)

Parenteral formulation development includes following activities but not limited to.

Identification, selection and optimization of composition (solubility enhancers, isotonicity agents, chelating agents, bulking agents, anti-oxidants, preservatives etc.)

Identification, selection and optimization of process and process parameters (mixing speed and mixing time, process temperature, order of addition of excipients etc.)

Product Container closure system identification, selection and finalization.

Other supporting studies such as in-use stability studies, preservative effectiveness testing, compatibility and hold time studies and stability studies, reconstitution studies and dilution studies.

Investing on us on the other hand, gives customers access to expansive equipment and facilities without taking on the expense of ownership. Our parenteral formulation development lab includes equipment such as Martin Christ 2-10D LSC plus pilot scale lyophilizer with a 10 liters condenser capacity, Fedegari counter pressure autoclave with 90 liters capacity and Memmert hot air oven. We are also equipped with IKA Ultraturrax’s T25 high shear mixer, Masterflex dosing pump and Laminar air flow system. The facility includes jacketed manufacturing vessels with one, two and five liters capacity, head space oxygen analyser, freezing point depression osmometer, conductivity meter, pH meter and Dissolved Oxygen meter. Validated stability chambers for conducting accelerated and prototype stability tests that support the selection of a lead and back-up formulation.

Throughout every step of drug product development, we are alongside customers helping them navigate the process and mitigate risk.

Our pareteral manufacturing facilities are located in Visakhapatnam and are audited by all major regulatory agencies.

Summary table:

Dosage form and Capabilities

Preclinical formulation support for GLP tox studies

Formulation and Analytical Development

cGMP Execution

Analytical Method Development

Composition Development

Process Development

Analytical Method Validation

Tech Transfer

Clinical batches & Supply / Commercial batches

Oral Solids








Granules in sachet


Oral Liquids

Oral solution/drops


Oral suspension


Oral emulsion










Aqueous liquid injectables


Non-aqueous liquid injectables


Lyophilized injectables


Ophthalmic and Optic solutions


Nasal Solutions

  • Denotes available services
  • Denotes services available through our strategic partners

Why Aurigene Pharmaceutical Services?

Fit-for-purpose development strategy

Co-located cross-functional teams such as PK-PD, API synthesis, salt screening, toxicology, process engineering and analytical development teams

Services across the product lifecycle

US FDA inspected GMP facilities

Virtual Tour


Contact Us

CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

JUNE 28, 2022

Neoantigen Specific T cells For Cancer Immunotherapy

Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...

Read More

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...

Read More

Technology meets sustainability - How a complex API development process goes green

We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...

Read More

Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug


Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...

Read More
View All

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.